NEW YORK (GenomeWeb) – Looking to expand beyond ion channel drug screening, Librede has begun work on developing its core artificial lipid bilayer technology for use in an automated nanopore-based platform for microRNA diagnostics.

With the support of a six-month, $224,000 grant from the National Cancer Institute, the company aims to develop a prototype system that can detect the small, non-coding RNAs cheaply and with off-the-shelf reagents, CEO Jason Poulos told GenomeWeb.

Once that work is complete, Librede aims to test its approach in clinical samples, he said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Sponsored by

In these times of economic constraint and increasing research costs, shared resource cores have become a cost-effective and essential platform for researchers who seek to investigate complex translational research questions.